Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pneumococcal disease

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

EU flag

Celgene’s Vidaza wins wider approval for acute myeloid leukaemia

Elderly patients to gain access to cancer drug

- PMLiVE

Allergan/Pfizer takeover talks confirmed

Talks still in early stage with no certainty of deal

- PMLiVE

Is Pfizer eyeing a merger with Allergan?

Combined company value could be $330bn

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

Pfizer’s investigational leukaemia drug wins breakthrough status

Puts inotuzumab ozogamacin in line for development incentives

- PMLiVE

FDA turns down Pfizer’s Xeljanz in psoriasis

USregulator dampens the firm's hope of expanding arthritis drug's uses

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

- PMLiVE

Europe’s health information systems to be modernised

Joint EC-WHO work will form a major strand of their renewedcollaboration

- PMLiVE

Pfizer launches first self-injectable contraceptive in UK

New option for female contraception hits UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links